Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edwards LifesciencesXSWX:EW 98 Net Cash per Share is CHF1.39 as of Jun. 2026, which is 100% below its 10-year median of 49.73. GuruFocus rates XSWX:EW with a GF Score™ of 98/100 and a GF Value™ of CHF75.68. The stock has 5 warning signs investors should review. Among 301 Medical Devices & Instruments companies, Edwards Lifesciences ranks worse than 89.37% on this metric.
The historical rank and industry rank for Edwards Lifesciences's Net Cash per Share or its related term are showing as below:
XSWX:EW'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 38.14 Med: 49.73 Max: 68.44
Current: 51.54
During the past 13 years, the highest Price-to-Net-Cash Ratio of Edwards Lifesciences was 68.44. The lowest was 38.14. And the median was 49.73.
XSWX:EW's Price-to-Net-Cash is ranked worse than 89.37% of 301
companies
in the Medical Devices & Instruments industry
Industry Median: 8.1
vs XSWX:EW: 51.54
Edwards Lifesciences (XSWX:EW) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Edwards Lifesciences Net Cash per Share Related Terms
Edwards Lifesciences Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Edwards Lifesciences's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:EW vs BSX, DXCM, GEHC: Net Cash per Share Comparison
For the Medical Devices subindustry, Edwards Lifesciences's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edwards Lifesciences Price-to-Net-Cash vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Edwards Lifesciences's Price-to-Net-Cash falls into.
Edwards Lifesciences Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Edwards Lifesciences's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edwards Lifesciences (XSWX:EW) has a Net Cash per Share of CHF1.39 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Edwards Lifesciences and its competitors. This is 97% below median its historical median of 49.73. Over the past decade, Edwards Lifesciences' Net Cash per Share has ranged from 38.14 to 68.44. According to the industry distribution chart, Edwards Lifesciences ranks #269 out of 301 companies in the Medical Devices & Instruments industry, placing it in the top 89.4%.
Is Edwards Lifesciences' Net Cash per Share too high?
Edwards Lifesciences' current Net Cash per Share of CHF1.39 is 97% below median its 10-year median of 49.73. Over the past 10 years, this metric has ranged from a low of 38.14 to a high of 68.44. Based on the distribution chart, Edwards Lifesciences ranks #269 out of 301 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Edwards Lifesciences has a GF Score™ of 98/100, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Net Cash per Share compare to BSX and DXCM?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #269 out of 301 companies for Net Cash per Share. This places Edwards Lifesciences in the lower half of its industry. The industry median Net Cash per Share is 8.10. Historically, Edwards Lifesciences' own Net Cash per Share has ranged from 38.14 to 68.44 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Devices & Instruments company?
The median Net Cash per Share among Medical Devices & Instruments companies is 8.10, based on 301 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Edwards Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median Net Cash per Share is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edwards Lifesciences's current Net Cash per Share is CHF1.39, which is 97% below median its own 10-year median of 49.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Edwards Lifesciences (XSWX:EW) has a current Net Cash per Share of CHF1.39. The stock's GF Value™ is CHF75.68, compared to a current price of CHF71.64 — trading 5.3% below its estimated fair value. The current Net Cash per Share is CHF1.39, which is 97% below median its 10-year median of 49.73. Edwards Lifesciences' overall GF Score™ is 98/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Edwards Lifesciences (XSWX:EW), the current Net Cash per Share is CHF1.39 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (XSWX:EW) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of CHF71.64 is trading 5.3% below its estimated GF Value™ of CHF75.68.
Key valuation signals for XSWX:EW:
Net Cash per Share: CHF1.39 (97% below median its 10-year median of 49.73)
GF Value™: CHF75.68 vs. price of CHF71.64 (5.3% below fair value)
No single metric tells the full story. See the XSWX:EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
98GF Score
Get the complete analysis for XSWX:EW
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EW has been successfully added to your 
